Zusammenfassung
Die Response Evaluation Criteria in Solid Tumors (RECIST) stellen die aktuell am weitesten etablierten radiologischen Bewertungskriterien für die standardisierte Beurteilung des Therapieansprechens bei soliden Tumoren dar. Für das Therapiemonitoring klassischer zytostatischer und zytotoxischer Tumortherapien wurde RECIST in zahlreichen klinischen Studien erfolgreich validiert. Das Therapieansprechen neuer molekularer Therapeutika lässt sich jedoch mitunter durch die konventionelle Bestimmung der Tumorgrößenänderung, wie bei RECIST, nicht erfassen. So wurden für die Evaluierung moderner Immuntherapien spezielle „immune-related“ Response Criteria (irRC) entwickelt.
Dieser Übersichtsartikel vermittelt ein radiologisches Grundlagenwissen der für das maligne Melanom am wichtigsten Responsekriterien RECIST 1.0 und 1.1 sowie irRC.
Abstract
In the field of oncology the response evaluation criteria in solid tumors (RECIST) currently represent the most commonly used and validated radiological response criteria for objective treatment monitoring of conventional chemotherapy. For therapy monitoring of classical cytostatic and cytotoxic tumor therapies RECIST has been tested and successfully validated in many clinical studies. However, with the introduction of novel molecular drugs limitations of these size-based criteria became obvious due to response patterns which are not reflected by RECIST. Thus, for a comprehensive evaluation of modern immunotherapeutic agents new immune-related response criteria (irRC) were developed.
This review gives a brief overview of the most important radiological response criteria RECIST 1.0 and 1.1 as well as irRC for malignant melanoma.
This is a preview of subscription content, log in via an institution to check access.
Literatur
WHO (1979) WHO handbook for reporting results of cancer treatment. World Health Organization Offset Publication No. 48, Geneva
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
Schwartz LH, Bogaerts J, Ford R et al (2009) Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer 45:261–267
Pflugfelder A, Kochs C, Blum A et al (2013) Malignant melanoma S3-guideline „diagnosis, therapy and follow-up of melanoma“. J Dtsch Dermatol Ges 11(Suppl 6):1–126
Wolchok JD, Hoos A, O’Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412–7420
Nishino M, Giobbie-Hurder A, Gargano M et al (2013) Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimentional measurements. Clin Cancer Res 19(14):3936–3943
Nishino M, Gargano M, Suda M et al (2014) Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer 2:1–17
Deutsche Röntgengesellschaft (DRG) (2014). http://www.onkologische-bildgebung.drg.de
Layer G, Stahl T, Hoffend J (2013) Bildgebende Beurteilung des Therapieansprechens unter Chemotherapie. Radiologie Up2date 13(03):221–239
Ganten MK, Ganten TM, Schlemmer HP (2014) Radiological monitoring of the treatment of solid tumors in practice. Rofo 186(5):466–473
Einhaltung ethischer Richtlinien
Interessenkonflikt. T. Persigehl, J. Spiro und D. Maintz geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Spiro, J., Maintz, D. & Persigehl, T. Responsekriterien bei malignem Melanom. Radiologe 55, 127–135 (2015). https://doi.org/10.1007/s00117-014-2763-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00117-014-2763-y